GDox

GDox (also known as GDOX) is a high molecular weight gelatin-doxorubicin conjugate designed for lysosomal targeting and intra-lysosomal drug release. Developed by researchers at the University of the Sciences in Philadelphia, GDox consists of the chemotherapeutic agent doxorubicin covalently linked to a gelatin backbone (molecular weight ~160 kDa) via an acid-labile hydrazone bond or EDC carbodiimide chemistry. This design allows the conjugate to remain stable at systemic pH but release doxorubicin in the acidic environment of lysosomes (pH ~4.8). GDox is being investigated in preclinical models for the treatment of breast cancer, including triple-negative breast cancer (TNBC), where it induces cytotoxicity through both nuclear and lysosomal membrane permeabilization (LMP) pathways.

Other names

gelatin-doxorubicingelatin-doxorubicin conjugate